PARP1 and cancer: Because the binding of PAR to hnRNP inhibit the RNA-binding activity of hnRNP A1, PARP inhibitors may have a therapeutic benefit for some hnRNP A1-dependent tumors by interfering with cancer cell metabolism (Figure 2d).